ATLAS fair value
₹1,130
Close to fair value · 3% premium
Zydus Lifesciences share price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · National Stock Exchange of India · India
Prices as of Oct 26, 2026 · INR
₹1,130
Close to fair value · 3% premium
52%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates Zydus Lifesciences's fair value at about ₹1,130 per share (reasonable range: ₹681.86 to ₹1,873). At ₹1,160, the stock trades within 8% of that figure: close to fair value.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is low. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Zydus Lifesciences a 52% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₹1,110 and ₹1,220; in 9 out of 10, between ₹1,021 and ₹1,326. Estimated annual volatility is 28%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Zydus Lifesciences sits close to fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks ZYDUSLIFE.NSE has traded between ₹835.50 and ₹1,232. Today it is 5.8% below that high and 39% above its low.
On the business: net margin is 15.8%; it trades at 25.2 times earnings.
Its beta is 0.37: it tends to move less than the market.
Zydus Lifesciences Ltd., formerly known as Cadila Healthcare, is a leading pharmaceutical company based in India, recognized for its commitment to innovation and healthcare excellence.
Want to see everything about Zydus Lifesciences?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About ₹1,130 per share according to ATLAS (reasonable range: ₹681.86 to ₹1,873). With the stock at ₹1,160, it is close to that value.
52%: close to a coin flip. In half of the simulated outcomes, ZYDUSLIFE.NSE ends the month between ₹1,110 and ₹1,220.
Zydus Lifesciences's market capitalization is ₹1.1T. Its price-to-earnings (P/E) ratio is 25.2: you pay ₹25.2 for each ₹1.00 of yearly earnings.
Yes. ZYDUSLIFE.NSE's current dividend yield is 0.35% at today's price (₹1,160).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy